Product Name:
JAK2-3
Product Number:
ab-nk084-5
Target Full Name: Janus protein-tyrosine kinase 2
Target Alias: JAK-2; Janus kinase 2; JTK10; Kinase JAK2 ; JAK2_ENST00000381652; JAK2_ENST00000381652; CCDS6457; A8K910; A9QVL8; B4DYV1; Q506Q0; Q52R86; Q8IXP2; ENSG00000096968
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK085-3
Antibody Target Type: Pan-specific
Protein UniProt: O60674
Protein SigNET: O60674
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human JAK2 sequence peptide Cat. No.: PE-01ARZ75
Antibody Immunogen Sequence: CDLALRVDQIRDNMAG
Antibody Immunogen Description: Corresponds to amino acid residues D1118 to G1132; Kinase last alpha-chain+C-terminus
Production Method: Corresponds to amino acid residues D1118 to G1132; Kinase last alpha-chain+C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 1 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with recombinant human JAK2 on protein dot blots.
Antibody Species Reactivity: Human; Mouse
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 125-135 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Weak immunoreactivity on protein dot blots with recombinant human JAK1, very weak immunoreactivity with JAK3, and no immunoreactivity with Tyk2.
Related Product 1: JAK2-3 blocking peptide
Related Product 2: JAK2-2 pan-specific antibody (Cat. No.: AB-NK085-2)
Related Product 3: JAK2 pan-specific antibody (Cat. No.: AB-NK085-3P)
Related Product 4: JAK2-4 pan-specific antibody (Cat. No.: AB-NK085-4)
Related Product 5: JAK2-pY1007+pY1008 phosphosite-specific antibody (Cat. No.: AB-PK667)
Related Product 6: JAK2-pY570 phosphosite-specific antibody (Cat. No.: AB-PK668)
Related Product 7: JAK2Selectide - JAK2 protein kinase substrate peptide
Related Product 8: IRS1 (891-902) KinSub - Insulin receptor substrate 1 (K891-G902) mouse, peptide; IGF1Rtide protein kinase substrate peptide
Related Product 9: IRS1 (891-902) KinSub - Insulin receptor substrate 1 (K891-G902) mouse, peptide; IGF1R protein kinase substrate peptide
Scientific Background: JAK2 is a protein-tyrosine kinase of the TK group and JAKA family. It is a non-receptor kinase involved in the regulation of various cellular processes, including cell cycle progression, development, differentiation, and histone modifications. Additionally, JAK2 plays a critical role in the signalling events of both innate and adaptive immunity as well as erythropoiesis. JAK2 can pair with type I receptors to mediate signalling for GHR (growth hormone), PRLR (prolactin), (LEPR) leptin, EPOR (erythropoietin), and THPO (thrombopoietin). JAK2 can also pair with type II receptors to mediate the effects of IFN-alpha, IFN-beta, IFN-gamma, and various interleukins. It is activated by phosphorylation at Y613, and Y972, and Y1008. JAK2 signalling has been implicated in in a wide range of human hematologic malignancies, and this is typically accompanied by the over-activation of the STAT5 transcription factor, which is a substrate. Polycythemia vera, thrombocythemia, and myelofibrosis are classified as clonal myeloproliferative diseases that arise from a multipotent progenitor cell type. These often rare diseases are characterized by excess production of abnormal cells, displacing healthy cells. JAK2 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. A high percentage of patients with these myeloproliferative diseases have a dominant gain-of-function substitution mutation, V617F, in the JAK2 gene sequence. For example, the V617F mutation was observed in 40 of 45 polycythemia vera patients. The mutation was observed to cause constitutive tyrosine phosphotransferase activity that promoted erythrocytosis in a mouse model.
